Taglich Brothers initiated CEL-SCI Corporation CVM with a Speculative Buy rating.
Taglich Brothers commented, "If Multikine secures regulatory clearance and launches in the US and Western Europe by 2018, it should, with relatively modest market penetration and a price per treatment of $50,000, achieve annualized revenue of $700 million (revenue per share of around $1.15) by 2020. … Multikine improves a patient's chance of survival by acting directly to destroy tumors and strengthening the immune system's response to the disease before it is compromised by surgery or radiation/chemotherapy."
CEL-SCI Corporation closed at $0.27 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in